Effect of COVID-19 Vaccination on Management of Chronic Migraine with Botulinum Toxin: A Case Series
Abstract
Introduction: Headache worsening has been previously reported following the coronavirus disease 2019 (COVID-19) vaccination. However, COVID vaccination's influence on managing chronic migraine (CM) with botulinum toxin is yet to be studied. Case Presentation: In this case series, we present five cases of CM, who had responded to abobotulinum toxin type A (BTX-A), but their number of headache days increased after COVID vaccination. Conclusions: In the case of vaccination with COVID vaccines, during the first month of administering botulinum toxin for the management of CM, there might be a decrease in the efficacy of botulinum toxin, which should be explained to the patients. The authors suggest that physicians postpone the administration of BTX-A for chronic migraine management to a later time at their discretion.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.